Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort
- PMID: 19360015
- PMCID: PMC2829436
- DOI: 10.1038/oby.2009.89
Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort
Abstract
Although nonalcoholic fatty liver disease (NAFLD) is frequent in obesity, the metabolic determinants of advanced liver disease remain unclear. Adipokines reflect inflammation and insulin resistance associated with obesity and may identify advanced NAFLD. At the time of obesity surgery, 142 consecutive patients underwent liver biopsy and had their preoperative demographic and clinical data obtained. Liver histology was scored by the NAFLD activity score, and patients subdivided into four groups. Concentrations of retinol-binding protein 4 (RBP4), adiponectin, tumor necrosis factor-alpha (TNF-alpha), and leptin were determined approximately 1 week prior to surgery and results were related to liver histology. The prevalence of no NAFLD was 30%, simple steatosis 23%, borderline nonalcoholic steatohepatitis (NASH) 28%, and definitive NASH 18%. Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS) prevalence were 39 and 75%, respectively, and did not differ across the four histological groups (P = NS). Triglyceride (TG) and alanine transaminase (ALT) levels, strongly associated with advanced stages of NAFLD and NASH (P = 0.04). TG levels >150 mg/dl, increased the likelihood of NASH 3.4-fold, whereas high-density lipoprotein (HDL) levels predicted no NAFLD (P < 0.01). Concentrations of TNF-alpha, leptin, and RBP4 did not differ among histological groups and thus did not identify NASH; however, there was a trend for adiponectin to be lower in NASH vs. no NAFLD (P = 0.061). In summary, both TG and ALT levels assist in identification of NASH in an obesity surgery cohort. These findings underscore the importance of fatty acid delivery mechanisms to NASH development in severely obese individuals.
Conflict of interest statement
The authors declared no conflict of interest.
Figures


Similar articles
-
Irisin in patients with nonalcoholic fatty liver disease.Metabolism. 2014 Feb;63(2):207-17. doi: 10.1016/j.metabol.2013.09.013. Epub 2013 Oct 18. Metabolism. 2014. PMID: 24140091
-
Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis?Eur J Gastroenterol Hepatol. 2010 Jul;22(7):813-9. doi: 10.1097/MEG.0b013e32833283cb. Eur J Gastroenterol Hepatol. 2010. PMID: 19820404
-
Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.World J Gastroenterol. 2013 Jul 7;19(25):4007-14. doi: 10.3748/wjg.v19.i25.4007. World J Gastroenterol. 2013. PMID: 23840146 Free PMC article.
-
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18. Adv Exp Med Biol. 2024. PMID: 39287864 Review.
-
Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease.Curr Pharm Des. 2010 Jun;16(17):1921-8. doi: 10.2174/138161210791208938. Curr Pharm Des. 2010. PMID: 20370670 Review.
Cited by
-
Evidence That Peripheral Leptin Resistance in Omental Adipose Tissue and Liver Correlates with MASLD in Humans.Int J Mol Sci. 2024 Jun 11;25(12):6420. doi: 10.3390/ijms25126420. Int J Mol Sci. 2024. PMID: 38928125 Free PMC article.
-
Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.Diabetologia. 2016 Jan;59(1):30-43. doi: 10.1007/s00125-015-3769-3. Epub 2015 Sep 26. Diabetologia. 2016. PMID: 26407715
-
Retinol binding protein 4 and fatty liver: A direct link?Hepatology. 2013 Aug;58(2):477-9. doi: 10.1002/hep.26507. Hepatology. 2013. PMID: 23703940 Free PMC article. No abstract available.
-
Protective effects of Spirulina maxima on hyperlipidemia and oxidative-stress induced by lead acetate in the liver and kidney.Lipids Health Dis. 2010 Mar 31;9:35. doi: 10.1186/1476-511X-9-35. Lipids Health Dis. 2010. PMID: 20353607 Free PMC article.
-
Nonalcoholic fatty liver disease: Diagnostic biomarkers.World J Gastrointest Pathophysiol. 2017 May 15;8(2):11-26. doi: 10.4291/wjgp.v8.i2.11. World J Gastrointest Pathophysiol. 2017. PMID: 28573064 Free PMC article. Review.
References
-
- Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis. 2004;8:535–547. viii. - PubMed
-
- Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16:421–427. - PubMed
-
- McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002;34:255–262. - PubMed
-
- Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345–32353. - PubMed
-
- Crespo J, Fernandez-Gil P, Hernandez-Guerra M, et al. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg. 2001;11:254–257. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous